Page last updated: 2024-11-10

prostaglandin e3

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

prostaglandin E3: Structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5280937
CHEMBL ID2074717
CHEBI ID28031
SCHEMBL ID3366416
MeSH IDM0103247

Synonyms (31)

Synonym
(5z,13e,15s,17z)-11alpha,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid
CHEBI:28031 ,
(5z,11alpha,13e,15s,17z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid
9-oxo-11r,15s-dihydroxy-5z,13e,17z-prostatrienoic acid
pge3
LMFA03010135
C06439
prostaglandin e3
802-31-3
delta(17)-pge1
pge1, delta(17)-
delta(17)-prostaglandin e1
SCHEMBL3366416
(z)-7-[(1r,2r,3r)-3-hydroxy-2-[(1e,3s,5z)-3-hydroxyocta-1,5-dienyl]-5-oxocyclopentyl]hept-5-enoic acid
CHEMBL2074717
zed6sbl53s ,
prosta-5,13,17-trien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5z,11alpha,13e,15s,17z)-
unii-zed6sbl53s
prosta-5,13,17-trien-1-oicacid, 11,15-dihydroxy-9-oxo-, (5z,11a,13e,15s,17z)-
prosta-5,13,17-trien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5z,11.alpha.,13e,15s,17z)-
AKOS027381955
7-[3-hydroxy-2-(3-hydroxy-1,5-octadienyl)-5-oxocyclopentyl]-5-heptenoic acid stereoisomer
(-)-prostaglandin e3
7-[3-hydroxy-2-(3-hydroxy-1,5-octadienyl)-5-oxocyclopentyl]-5-heptenoic acid
7-[3-hydroxy-2-(3-hydroxy-1,5-octadienyl)-5-oxocyclopentyl]-5-heptenoate
sr-01000946848
SR-01000946848-1
Q15708280
(5z,11.alpha.,13e,15s,17z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid
9-oxo-11alpha,15s-dihydroxy-prosta-5z,13e,17z-trien-1-oic acid
DTXSID301045731
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
prostaglandins E
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Folic acid network070
Selenium micronutrient network095

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier organic anion transporter family member 3A1Homo sapiens (human)Km0.05550.04850.05200.0555AID681367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
positive regulation of protein phosphorylationSolute carrier organic anion transporter family member 3A1Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 3A1Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 3A1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 3A1Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activitySolute carrier organic anion transporter family member 3A1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 3A1Homo sapiens (human)
transport across blood-brain barrierSolute carrier organic anion transporter family member 3A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 3A1Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 3A1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 3A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier organic anion transporter family member 3A1Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 3A1Homo sapiens (human)
apical plasma membraneSolute carrier organic anion transporter family member 3A1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 3A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID681367TP_TRANSPORTER: uptake in Xenopus laevis oocytes2003American journal of physiology. Renal physiology, Dec, Volume: 285, Issue:6
Molecular characterization of human and rat organic anion transporter OATP-D.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (79)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (24.05)18.7374
1990's14 (17.72)18.2507
2000's21 (26.58)29.6817
2010's22 (27.85)24.3611
2020's3 (3.80)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.46 (24.57)
Research Supply Index4.45 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (6.25%)5.53%
Reviews2 (2.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other73 (91.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]